Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Carboxylic Acids
Clear Filters

Search Clinical Trials

11 Results
Enrolling By Invitation
Post-operative Pain Management in Children With Supracondylar Humerus Fractures
Prior to surgery, participants will be randomly assigned to a group that will determine whether they are prescribed an opioid vs non-opioid pain management plan at discharge. Each participants' parent …
Baylor Role: Lead Sponsor
Recruiting
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Transitioning from busulfan, hydroxyurea, IFN-α to tyrosine kinase inhibitors (TKIs) has dramatically altered the natural history of CML. Patients with CML appropriately managed with TKIs are able to benefit from …
Baylor Role: Lead Sponsor
Withdrawn
Tranexamic Acid in Adherent Placenta (TAP)
This trial is a randomized, double blind, placebo controlled trial to quantify the effects of the preoperative administration of tranexamic acid on estimated blood loss and blood product utilization in …
Baylor Role: Lead Sponsor
Completed
Tranexamic Acid Per Inhalation for Treatment of Pulmonary Hemorrhage in Pediatric Patients
Pulmonary hemorrhage can be severe and life-threatening. In children, etiologies of pulmonary hemorrhage include respiratory infection, foreign bodies, bronchiectasis, pulmonary vascular disorders, parenchymal lung disease, and post-surgical complications. Initial management …
Baylor Role: Lead Sponsor
Completed
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
The investigators will study and compare how effectively sodium phenylbutyrate, sodium benzoate, and a combination of the two, help excrete nitrogen in healthy volunteers. Subject participation will require three, separate, …
Baylor Role: Lead Sponsor
Terminated
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
For patients with stage IIIB/IV non-small cell lung cancer, who did not progress after first line chemotherapy, lenalidomide 10mg/day orally will be administered as maintenance therapy until disease progression or …
Baylor Role: Collaborator
Unknown Status
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER
Current treatment of neurogenic bladder dysfunction (NGB) is limited by the suboptimal results achieved using standard antimuscarinic agents. A prominent role for the actions of alternative transmitters/growth factors in peripheral …
Terminated
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Previously, some of the cancer cells were taken from the subject's body and separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was …
Baylor Role: Lead Sponsor
Completed
Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study
Subjects were randomized to one of two groups (group A or B). Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator